Literature DB >> 35857090

Eye movement indices as predictors of conversion to psychosis in individuals at clinical high risk.

Lihua Xu1, Dan Zhang1, Yuou Xie2, Xiaochen Tang1, Yegang Hu1, Xu Liu1, Guisen Wu1, Zhenying Qian1, Yingying Tang1, Zhi Liu3,4, Tao Chen5,6,7, HaiChun Liu8, Tianhong Zhang9, Jijun Wang10,11,12.   

Abstract

Eye movement abnormalities have been established as an "endophenotype" of schizophrenia. However, less is known about the possibility of these abnormalities as biomarkers for psychosis conversion among clinical high risk (CHR) populations. In the present study, 108 CHR individuals and 70 healthy controls (HC) underwent clinical assessments and eye-tracking tests, comprising fixation stability and free-viewing tasks. According to three-year follow-up outcomes, CHR participants were further stratified into CHR-converter (CHR-C; n = 21) and CHR-nonconverter (CHR-NC; n = 87) subgroups. Prediction models were constructed using Cox regression and logistic regression. The CHR-C group showed more saccades of the fixation stability test (no distractor) and a reduced saccade amplitude of the free-viewing test than HC. Moreover, the CHR-NC group exhibited excessive saccades and an increased saccade amplitude of the fixation stability test (no distractor; with distractor) compared with HC. Furthermore, two indices could effectively discriminate CHR-C from CHR-NC with an area under the receiver-operating characteristic (ROC) curve of 0.80, including the saccade number of the fixation stability test (no distractor) and the saccade amplitude of the free-viewing test. Combined with negative symptom scores of the Scale of Prodromal Symptoms, the area was 0.81. These findings support that eye movement alterations might emerge before the onset of clinically overt psychosis and could assist in predicting psychosis transition among CHR populations.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Eye movement; Schizophrenia; Transition; Ultra high risk

Year:  2022        PMID: 35857090     DOI: 10.1007/s00406-022-01463-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.760


  45 in total

1.  Saccadic eye movements as markers of schizophrenia spectrum: Exploration in at-risk mental states.

Authors:  Simona Caldani; Maria Pia Bucci; Jean-Charles Lamy; Magali Seassau; Narjes Bendjemaa; Rémi Gadel; Raphael Gaillard; Marie-Odile Krebs; Isabelle Amado
Journal:  Schizophr Res       Date:  2016-09-14       Impact factor: 4.939

2.  Simple viewing tests can detect eye movement abnormalities that distinguish schizophrenia cases from controls with exceptional accuracy.

Authors:  Philip J Benson; Sara A Beedie; Elizabeth Shephard; Ina Giegling; Dan Rujescu; David St Clair
Journal:  Biol Psychiatry       Date:  2012-05-22       Impact factor: 13.382

3.  Failures in top-down control in schizophrenia revealed by patterns of saccadic eye movements.

Authors:  Sonia Bansal; Benjamin M Robinson; Carly J Leonard; Britta Hahn; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2019-06-13

4.  Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk.

Authors:  Paolo Fusar-Poli; Ilaria Bonoldi; Alison R Yung; Stefan Borgwardt; Matthew J Kempton; Lucia Valmaggia; Francesco Barale; Edgardo Caverzasi; Philip McGuire
Journal:  Arch Gen Psychiatry       Date:  2012-03

5.  A study on negative and depressive symptom prevalence in individuals at ultra-high risk for psychosis.

Authors:  Marleine Azar; Marita Pruessner; Lawrence H Baer; Srividya Iyer; Ashok K Malla; Martin Lepage
Journal:  Early Interv Psychiatry       Date:  2016-09-21       Impact factor: 2.732

6.  An Individualized Risk Calculator for Research in Prodromal Psychosis.

Authors:  Tyrone D Cannon; Changhong Yu; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Clark D Jeffries; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Michael W Kattan
Journal:  Am J Psychiatry       Date:  2016-07-01       Impact factor: 18.112

7.  Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.

Authors:  Tyrone D Cannon; Yoonho Chung; George He; Daqiang Sun; Aron Jacobson; Theo G M van Erp; Sarah McEwen; Jean Addington; Carrie E Bearden; Kristin Cadenhead; Barbara Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana Perkins; Clark Jeffries; Larry J Seidman; Ming Tsuang; Elaine Walker; Scott W Woods; Robert Heinssen
Journal:  Biol Psychiatry       Date:  2014-06-12       Impact factor: 13.382

8.  Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: Associations with clinical outcomes.

Authors:  Huiru Cui; Anthony J Giuliano; Tianhong Zhang; Lihua Xu; Yanyan Wei; Yingying Tang; Zhenying Qian; Lena M Stone; Huijun Li; Susan Whitfield-Gabrieli; Margaret Niznikiewicz; Matcheri S Keshavan; Martha E Shenton; Jijun Wang; William S Stone
Journal:  Schizophr Res       Date:  2020-07-18       Impact factor: 4.939

9.  Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample.

Authors:  H Magnus Haraldsson; Ulrich Ettinger; Brynja B Magnusdottir; Thordur Sigmundsson; Engilbert Sigurdsson; Hannes Petursson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04-24       Impact factor: 5.270

10.  The relation between antisaccade errors, fixation stability and prosaccade errors in schizophrenia.

Authors:  Jason J S Barton; Manisha Pandita; Katy Thakkar; Donald C Goff; Dara S Manoach
Journal:  Exp Brain Res       Date:  2007-12-05       Impact factor: 1.972

View more
  1 in total

Review 1.  Visual system assessment for predicting a transition to psychosis.

Authors:  Alexander Diamond; Steven M Silverstein; Brian P Keane
Journal:  Transl Psychiatry       Date:  2022-08-29       Impact factor: 7.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.